文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

中危前列腺癌患者大分割放疗与常规放疗的成本效果分析:PROFIT试验的辅助研究

Cost-effectiveness of hypofractionated versus conventional radiotherapy in patients with intermediate-risk prostate cancer: An ancillary study of the PROstate fractionated irradiation trial - PROFIT.
PubMed 文献 · Radiother Oncol · 2022-06-27

该研究为PROFIT随机临床试验的辅助成本效果分析,纳入法国六家癌症中心的222例中危前列腺癌患者,从支付方视角比较中度大分割放疗(H-RT)与常规放疗(C-RT)48个月内的成本与质量调整生命年。H-RT组每例总成本低于C-RT组(3062欧元 vs 4285欧元,p<0.05),QALY差异为0.044(95%CI:-0.016至0.099),未达统计学显著。作者认为中度H-RT可减少国家医保支出,采用更新报销定价可改善放疗资源分配。

要点

  • H-RT组每例总成本3062欧元,低于C-RT组的4285欧元(p<0.05)。
  • H-RT组QALY较C-RT组高0.044(95%CI:-0.016至0.099),差异未达统计学显著。
  • 作者认为中度H-RT可减少国家医保支出,更新报销定价可改善资源分配。

核心结论

  • 作者认为,对局部前列腺癌采用中度H-RT可减少国家医保支出。
  • 作者认为,采用该治疗并更新报销定价将改善放疗管理中的资源分配。

研究设计与样本

  • 研究为国际PROFIT试验的辅助研究,是一项前瞻性随机临床试验,纳入法国六家癌症中心的222例中危前列腺癌患者。
  • 研究从支付方视角开展成本效果分析,时间跨度为48个月。
  • H-RT组接受6000 cGy分20次、4周内完成;C-RT组接受7800 cGy分39次、7至8周内完成。
  • 患者在基线、24个月和48个月完成EPIC生活质量问卷,并映射为EQ-5D以生成QALY。
  • 采用广义线性模型评估两组QALY与成本差异,成本以2020年欧元计,采用非参数自举法估算增量成本效果比(ICER)。

主要发现

  • H-RT组每例总成本为3062欧元(95%CI:2368至3754),C-RT组为4285欧元(95%CI:3355至5215),H-RT组低于C-RT组(p<0.05)。
  • H-RT组QALY较C-RT组高0.044(95%CI:-0.016至0.099),该差异未达统计学显著。

关键数值与推荐

  • H-RT组放疗方案为6000 cGy分20次、4周内完成。
  • C-RT组放疗方案为7800 cGy分39次、7至8周内完成。
  • 成本效果分析时间跨度为48个月,成本以2020年欧元计。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the cost-effectiveness of moderate Hypofractionated Radiotherapy (H-RT) compared to Conventional Radiotherapy (C-RT) for intermediate-risk prostate caner (PCa). METHODS: A prospective randomized clinical trial including 222 patients from six French cancer centers was conducted as an ancillary study of the international PROstate Fractionated Irradiation Trial (PROFIT). We carried-out a cost-effectiveness analysis (CEA) from the payer's perspective, with a time horizon of 48 months. Patients assigned to the H-RT arm received 6000 cGy in 20 fractions over 4 weeks, or 7800 cGy in 39 fractions over 7 to 8 weeks in the C-RT arm. Patients completed quality of life (QoL) questionnaire: Expanded Prostate Cancer Index Composite (EPIC) at baseline, 24 and 48 months, which were mapped to obtain a EuroQol five-dimensional questionnaire (EQ-5D) equivalent to generate Quality Adjusted Life Years (QALY). We assessed differences in QALYs and costs between the two arms with Generalized Linear Models (GLMs). Costs, estimated in euro (€) 2020, were combined with QALYs to estimate the Incremental Cost-effectiveness ratio (ICER) with non-parametric bootstrap. RESULTS: Total costs per patien were lower in the H-RT arm compared to the C-RT arm €3,062 (95 % CI: 2,368 to 3,754) versus €4,285 (95 % CI: 3,355 to 5,215), (p < 0.05). QALY were marginally higher in the H-RT arm, however this difference was not significant: 0.044 (95 % CI: - 0.016 to 0.099). CONCLUSIONS: Treating localized prostate cancer with moderate H-RT could reduce national health insurance spending. Adopting such a treatment with an updated reimbursement tariff would result in improving resource allocation in RT management.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Zhou K, Renouf M, Perrocheau G, et al. Cost-effectiveness of hypofractionated versus conventional radiotherapy in patients with intermediate-risk prostate cancer: An ancillary study of the PROstate fractionated irradiation trial - PROFIT. Radiother Oncol. 2022. PMID: 35772576. doi:10.1016/j.radonc.2022.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。